Go Pro
→ Trump and Bernie agree on this (From Porter & Company) (Ad)tc pixel
LON:SCLP

Scancell Interim Earnings Report

Scancell logo
GBX 10.16 +0.07 (+0.64%)
As of 09/11/2026 12:38 PM Eastern
ProfileEarnings History

Scancell EPS Results

Actual EPS
-GBX 0.55
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scancell Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scancell Announcement Details

Quarter
Interim
Date
1/29/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Scancell Earnings Headlines

Scancell (LON:SCLP) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened
September 11 at 2:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31016137
Scancell to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scancell-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference-1036519305
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet production stayed at 5.9 million ounces, unchanged from 2020. Newmont, Barrick and Agnico all face the same reserve shortage, pushing majors toward acquiring smaller producing miners. Recent deals show the pattern: Rupert Resources jumped 67 percent and G2 Goldfields jumped 79 percent the day their buyouts were announced. Analyst Garrett Goggin has identified four junior miners he believes are next on the shopping list.tc pixel
September 12 at 1:00 AM  |  Golden Portfolio (Ad)
Scancell (LON:SCLP) Shares Pass Below Two Hundred Day Moving Average - Here's What Happened
September 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31000106
Empire Metals, Vast Resources, Rockfire Resources, Oxford Nanopore Technologies, Scancell
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/video/empire-metals-vast-resources-rockfire-085806824.html
Scancell secures UK clearance for late-stage melanoma trial
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scancell-secures-uk-clearance-stage-061100982.html
See More Scancell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scancell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scancell and other key companies, straight to your email.

About Scancell

Scancell (LON:SCLP) (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+ brings benefit to, in combination with CPIs, has been identified, enabling precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., has been established with the intention to develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S.

View Scancell Profile
Earnings Tools